Anabolic steroidAndrogenNon-aromatisingOralDesigner steroidProgestin

Methoxygonadiene (Max LMG)

Also known as Max LMG · Methoxydienone · Methoxygonadiene · 13-ethyl-3-methoxy-gona-2,5(10)-dien-17-one

Written by enwyReviewed 4 Aug 20262 sources0 comments

Methoxygonadiene (Max LMG) is a progestin-derived prohormone that converts toward the potent progestin/anabolic promagnon-type steroid. Used as a non-aromatising 'wet' bulking base with anti-estrogen synergy, its effects and its progestogenic risks are documented only anecdotally.

01 Overview

Methoxygonadiene (also called Max LMG or methoxydienone) is a 13-ethyl gonane steroid related to the progestin family. In the body it is thought to convert to an active progestin/anabolic compound (a promagnon/tetrahydrogestrinone-adjacent structure), giving it a reputation as a non-aromatising 'base' compound that stacks well and adds fullness without direct estrogen conversion.

Because its lineage is progestational, the main concerns are progestogenic side effects — libido changes and potential gynecomastia via progesterone-receptor activity — alongside HPTA suppression. It is not 17-alpha-methylated, so liver strain is comparatively lower than the alkylated designer steroids. No controlled human data exist; all claims are anecdotal or inferred from related progestins. It is treated as a designer steroid under sport and drug regulations.

02 Mechanism

13-ethylgonane progestin derivative converting to an active progestin/anabolic steroid that binds androgen and progesterone receptors; does not aromatise.

03 Dosing

Tier	Dose	Route	Notes
Common (marketed)	25–75 mg/day	Oral	Historic labelled dosing, often as a stack base over 4-6 weeks.

Ester comparison

Ester	Half-life	Injection freq.	Testosterone by mass

04 Effects

Effect	Magnitude	Evidence
Fullness / lean gainReported fullness and steady lean gains as a bulking base.	modest	Anecdotal
Stacks without added estrogenNon-aromatising nature makes it a popular base to pair with other prohormones.	n/a	Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence	Countermeasures
Progestogenic effects (libido loss, gyno risk)Reduced libido and progesterone-mediated gynecomastia risk reported.	Moderate	Common	Anecdotal
HPTA suppressionTestosterone suppression requiring recovery support.	Moderate	Near-universal	Anecdotal

06 Legal status

United Kingdom

Class C

Falls under anabolic steroid provisions. · as of Jan 2026

United States

Designer steroid / grey market

Treated as a designer anabolic steroid; regulatory status contested but prohibited in sport. · as of Jan 2026

07 References

Methoxygonadiene / methoxydienone metabolism and detectionDrug Testing and Analysis

Designer progestin-derived steroids in supplementsPubMed

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.